Chromocell Therapeutics Corporation (CHRO) - Kompaniya qiymatining sof foydaga nisbati
Chromocell Therapeutics (CHRO) molekulalar sintezi va klinik sinovlarni tashqi pudratchilarga topshirishga asoslangan virtual R&D modeliga tayanadi. -0.80 indikatori aks etgan narxlar grafigi opioid xavflarisiz surunkali og'riqlarga qarshi kurashish uchun mo'ljallangan xavfsiz va selektiv ingibitorlarning ishlab chiqilishiga hamrohlik qiladi. Biomeditsinaning neytral maqomi global mojarolar va sanksiyalarning kompaniya faoliyatiga ta'sirini minimallashtirib, barqaror operatsion muhitni ta'minlaydi.
%20Narxning%20foydaga%20nisbati&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_CHRO_-_Chromocell-Therapeutics_-_Price-to-Earnings-Ratio "Chromocell Therapeutics (CHRO): Kompaniya qiymatining sof foydaga nisbati 21.02.2024dan 02.07.2025gacha | 👁️GURU.Markets👁️")
Chromocell Therapeutics kompaniyasining tahliliy kesimlari
- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi ko'rsatkichlari:
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Umumiy qarzning xususiy kapitalga nisbati Chromocell Therapeutics|CHRO - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli majburiyatlarning kapitalga nisbati Chromocell|CHRO - Kompaniyaning jamlangan qarzlari|Qarzning balans qiymatiga nisbati Chromocell Therapeutics Corp.|CHRO - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz Chromocell Therapeutics|Tezkor likvidlik chromocell.com
- foyda va baholash multiplikatorlari ko'rsatkichlari:
CHRO - Kompaniyaning sof foydasi|Kutilayotgan foyda Chromocell Therapeutics|CHRO - Narx-foyda koeffitsiyenti|Kelajakdagi narx-foyda multiplikatori Chromocell Therapeutics Corp|CHRO - Narx-foyda va o‘sish multiplikatori|Korxona qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati koeffitsiyenti Chromocell Therapeutics Corp.|CHRO - EBITDA operatsion foydasi|Sirpanuvchi yil uchun bir aksiya uchun foyda Chromocell Therapeutics|CHRO - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi o'n ikki oy davomida yillik hisobda bir aksiya uchun foyda o'sishi chromocell.com|CHRO - Joriy yilda bir aksiya uchun foyda o'sishi|Keyingi yilda bir aksiya uchun foydaning kutilayotgan dinamikasi Chromocell Therapeutics
Kompaniyaning jamlanma tahlili:CHRO chromocell.com
P/E koeffitsiyenti aksiyaning bozor qiymatini sof foydaga nisbatan o'lchaydi va investorning foyda birligi uchun to'laydigan premiumini aks ettiradi. Ushbu metrika xarajatlarning ortishi biznes marjalariga ko'rsatadigan ta'sirini aniqlaydi. Opioid alternativlarini ishlab chiqishning R&D bosqichida bo'lgan Chromocell Therapeutics (CHRO) uchun ushbu ko'rsatkich ko'pincha daromadlilikning yo'qligi sababli buzilgan bo'ladi. Kompaniyaning tarixiy P/E grafigini tahlil qilish investorlarga spekulyativ sakrashlarni haqiqiy o'sishdan ajratish imkonini beradi, bu esa biotexnologiya sektorida xatarlarni baholash uchun juda muhimdir.
Muhim raqobatchilar
Narx-foyda koeffitsiyenti biogen.com (BIIB)|P/E multiplikatori NBIX|RGC (Regencell Bioscience Ltd) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Axsome Therapeutics Inc AXSM|Kompaniya qiymatining sof foydaga nisbati ACAD|XENE - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati vikingtherapeutics.com|Supernus (SUPN) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti Catalyst Pharma|Narxning foydaga nisbati Denali Therapeutics Inc|Kapitalizatsiyaning foydaga nisbati Harmony Corp HRMY|P/E multiplikatori BHVN|Narx-foyda koeffitsiyenti amylyx.com AMLX|P/E multiplikatori TRVI (Trevi Therapeutics, Inc.)|Praxis Precision Medicines Inc (PRAX) - Kapitalizatsiyaning foydaga nisbati|AVXL - Narxning foydaga nisbati|CBLL: Narxning foydaga nisbati|prothena.com (PRTA) - Narxning foydaga nisbati|ALEC (Alector) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti ANNX|OMER: Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti NGNE (Neurogene Corp)|Bozor narxining sof foydaga nisbati ACIU|P/E multiplikatori VYGR (Voyager Therapeutics)|Kompaniya qiymatining sof foydaga nisbati NMRA|Scilex - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Tevogen Bio Holdings Inc.|alphacognition.com (ACOG) - Narxning foydaga nisbati|Cognition Therapeutics Inc. - Kompaniya qiymatining sof foydaga nisbati|IKT (Inhibikase Therapeutics) - P/E multiplikatori|P/E multiplikatori cassavasciences.com|Narxning foydaga nisbati Assertio Holdings, Inc. (ASRT)|COYA: Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori VTGN (Vistagen)|Ovid Therapeutics Inc (OVID) - Kapitalizatsiyaning foydaga nisbati|ABOS: Narx-foyda koeffitsiyenti|CRVO - P/E multiplikatori|ATHE (alteritytherapeutics.com) - Narx-foyda koeffitsiyenti|CLNN: Bozor narxining sof foydaga nisbati|PEPG (PepGen Inc) - P/E multiplikatori|Jupiter Neurosciences, Inc. (JUNS) - Biznesning o‘zini qoplash muddati|P/E multiplikatori RLMD|Narx-foyda koeffitsiyenti annovisbio.com ANVS|Narxning foydaga nisbati Grace Therapeutics GRCE|Biznesning o‘zini qoplash muddati Firefly Neuroscience, Inc. (AIFF)|ANEW Medical, Inc. - P/E multiplikatori|NeuroSense Therapeutics (NRSN) - Narx-foyda koeffitsiyenti|RVPH: P/E multiplikatori|MetaVia - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati NeurAxis|HSDT: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Passage Bio, Inc. (PASG)|NEUP - Kapitalizatsiyaning foydaga nisbati|Narxning foydaga nisbati Minerva Neurosciences NERV|ATHA: Narx-foyda multiplikatori|Addex Therapeutics Ltd - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Alzamend Neuro, Inc.|CYCN (cyclerion.com) - Narx-foyda koeffitsiyenti|Protagenic Therapeutics, Inc. (PTIX) - P/E multiplikatori|Narxning foydaga nisbati Pasithea Therapeutics Corp|CRGT: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Avenue Therapeutics, Inc. (ATXI)|BCLI - Kapitalizatsiyaning foydaga nisbati|P/E multiplikatori CARA (Cara Therapeutics, Inc)|ELYM - Narx-foyda koeffitsiyenti|Intra-Cellular - P/E multiplikatori|Kompaniya qiymatining sof foydaga nisbati LBPH (longboardpharma.com)|Marinus Pharmaceuticals, Inc. (MRNS) - Narxning foydaga nisbati|NKGen Biotech Inc - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati NeuroBo|Kapitalizatsiyaning foydaga nisbati Sage Therapeutics Inc SAGE|Narxning foydaga nisbati Synaptogenix, Inc. (SNPX)|Narx-foyda koeffitsiyenti trevena.com TRVN|Narxning foydaga nisbati Vigil Neuroscience, Inc. VIGL|anewmeds.com (WENA) - Kapitalizatsiyaning foydaga nisbati|Cerevel - P/E multiplikatori
